Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

Publisher： Karger

E-ISSN： 1421-9824|14|2|84-89

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.14, Iss.2, 2002-07, pp. : 84-89

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 20, Iss. 2-3, 2005-08 ,pp. : 120-132

Karger

Access to resources Recommend Favorite

Donepezil for the Treatment of Mild to Moderate Alzheimer’s Disease in France: The Economic Implications

By  

Dementia and Geriatric Cognitive Disorders, Vol. 17, Iss. 1-2, 2003-12 ,pp. : 5-13

Karger

Access to resources Recommend Favorite

Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment

By  

Neuroepidemiology, Vol. 28, Iss. 2, 2007-04 ,pp. : 116-117

Karger

Access to resources Recommend Favorite

Differential Efficacy of Treatment with Acetylcholinesterase Inhibitors in Patients with Mild and Moderate Alzheimer’s Disease over a 6-Month Period

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 4, 2005-03 ,pp. : 189-195

Karger

Access to resources Recommend Favorite

Galantamine: Additional Benefits to Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 11, Iss. 1, 2000-09 ,pp. : 19-27

Karger

Access to resources Recommend Favorite